Seres Therapeutics, Inc.
MCRB
$9.31
-$0.77-7.64%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -99.95% | -99.71% | 2,380.87% | 1,672.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -99.95% | -99.71% | 2,380.87% | 1,672.24% |
| Cost of Revenue | -51.62% | -67.86% | -73.72% | -56.98% | -43.03% |
| Gross Profit | -273.75% | -207.77% | 4.81% | 129.18% | 116.55% |
| SG&A Expenses | -32.45% | -36.97% | -28.88% | -7.97% | 5.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -102.99% | -102.68% | -102.30% | -19.03% | 469.02% |
| Total Operating Expenses | -43.60% | -47.43% | -45.29% | -25.63% | -9.86% |
| Operating Income | -25.60% | -2.38% | -2.75% | 72.57% | 58.35% |
| Income Before Tax | -39.18% | -18.09% | 3.05% | 73.82% | 59.88% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -39.18% | -18.09% | 3.05% | 73.82% | 59.88% |
| Earnings from Discontinued Operations | 1,145.71% | 2,048.82% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 100.12% | 81.97% | -5.66% | 68.76% | 54.54% |
| EBIT | -25.60% | -2.38% | -2.75% | 72.57% | 58.35% |
| EBITDA | -28.06% | -2.67% | -2.88% | 74.39% | 59.81% |
| EPS Basic | 99.85% | 79.80% | 4.73% | 73.98% | 62.17% |
| Normalized Basic EPS | -3.14% | -1.97% | 13.18% | 78.48% | 66.45% |
| EPS Diluted | 99.14% | 79.56% | 4.85% | 73.75% | 61.96% |
| Normalized Diluted EPS | -2.37% | -1.41% | 13.59% | 78.22% | 66.20% |
| Average Basic Shares Outstanding | 21.40% | 14.47% | 10.92% | 14.26% | 18.48% |
| Average Diluted Shares Outstanding | 20.90% | 13.99% | 10.45% | 14.72% | 18.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |